LLYEli Lilly and CompanySigning up patients
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast Neoplasms · Neoplasm Metastasis
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 800 (planned)
- Started
- Dec 22, 2025
- Main results expected
- May 2029
- Fully finished
- May 2033
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
(Part 1): Overall Response Rate (ORR): Percentage of Participants with Confirmed Complete Response (CR) or Partial Response (PR)
Measured over: Baseline through disease progression or death (Estimated up to 5 years)
(Part 2): Progression-Free Survival
Measured over: Baseline to objective progression or death due to any cause (Estimated up to 5 years)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07174336 · record last updated 2026-11-04 · checked 2026-11-09 15:42 UTC